Skip to main content
Premium Trial:

Request an Annual Quote

Johns Hopkins Spinout PGDx Raises $4.3M

NEW YORK (GenomeWeb) – Personal Genome Diagnostics has raised $4.3 million in private financing, the firm said in a document filed with the US Securities and Exchange Commission on Wednesday. 

A spokesperson for the firm said that the financing was in the form of a convertible note funding and is part of a larger Series A round currently underway. No further details were disclosed. 

The Baltimore-based Johns Hopkins University spinout did not disclose the identities of the investors, but said in its SEC document that there were 18. It did not say how proceeds from the funding will be used. 

PGDx offers next-generation sequencing-based cancer diagnostic panels, including a clinical targeted sequencing panel, and research-based sequencing services for tissue- and blood-based tumor profiling. Officials from the firm told GenomeWeb earlier this year that it plans to take its products through US Food and Drug Administration clearance. 

Last year, PGDx raised $2.8 million in a private financing round.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.